Survodutide cuts weight 13.1% in phase 3 diabetes trial
Boehringer Ingelheim's glucagon/GLP-1 dual agonist also lowered HbA1c by up to 1.21 points over 76 weeks, with 18% discontinuing for gastrointestinal events.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 6 05:22 ETSource: Pharmafile
The wire
- 01In SYNCHRONIZE-2, survodutide produced up to 13.1% weight loss at 76 weeks versus 3.1% with placebo, and 79.3% of treated patients lost at least 5% of body weight.
- 02HbA1c fell up to 1.21 percentage points from a 7.4% baseline, waist circumference dropped 11.1cm, and up to 29.5% reached HbA1c below 5.7% versus 4% on placebo.
- 03Gastrointestinal adverse events drove 18% discontinuation versus 1.2% on placebo, mostly during dose escalation; survodutide is not approved. Data presented at EASD and published in NEJM.
From the source
Read at pharmafile.comSurvodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
pharmafile | October 6, 2026 | News story | | Diabetes , GLP-1 , Obesity , diabetes , obesity , phase 3 trial
